Acetylsalycylic acid resistance and risk factors in acute ischemic stroke patients
Turk Beyin Damar Hastaliklar Dergisi, vol.21, no.1, pp.23-29, 2015 (Scopus)
- Publication Type: Article / Article
- Volume: 21 Issue: 1
- Publication Date: 2015
- Doi Number: 10.5505/tbdhd.2015.41736
- Journal Name: Turk Beyin Damar Hastaliklar Dergisi
- Journal Indexes: Scopus
- Page Numbers: pp.23-29
- Keywords: ASA resistance, Cerebrovascular ischemic stroke, PFA 100 test, Risk factors
- Ankara Yıldırım Beyazıt University Affiliated: Yes
Abstract
Objective: The aim of the study was to investigate prevalence of acetylsalicylic acid (ASA) resistance in acute ischemic stroke patients by using Platelet Function Analyzer (PFA) 100 test and to determine the effect of risk factors that may be responsible for ASA resistance. METHODS: Fifty acute ischemic stroke patients (mean age: 66.32±12.983 years, 34 male) were given 300 mg/day aspirin for at least 10 days and all risk factors were investigated for a correlation to ASA resistance by using PFA 100 test. These factors were; age, gender, hemoglobin (Hgb), hematocrit (Htc), platelet (plt) total cholesterol, von Willebrand Factor (VWF) levels, hypertension (HT), diabetes mellitus (DM), coronary artery disease (CAD), smoking and previous cerebrovascular disease (CVD). In PFA-100 system, a collagen/epinephrine (C/EPI) closure time in the range of 85-157 sec. and a collagen/ADP closure time of 65-125 sec. were considered normal. Maximal test duration was 300 s. C/EPI closure time is sensitive for ASA resistance. Subjects with duration shorter than 300 s. were accepted as ASA-resistant or non-responder. RESULTS: ASA resistance was apparent in 32% of the study group. VWF levels were higher in ASA resistant patients group. All risk factors were compared in ASA sensitive and resistant group. VWF levels and mean age were higher in ischemic stroke ASA non responder group, but not statistically significant. CONCLUSION: In 50 acute ischemic patient aspirin resistance rate was 32%, this means aspirin was pharmacologically non effective in those. Clinical outcome for aspirin non responders may be revealed through the follow up at least six months.